Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 14/20 | 0.82 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806962 | 1.00 | NOD1 (0.82) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8295104 | 0.90 | NOD1 (0.88) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8292861 | 0.90 | NOD1 (0.88) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8294528 | 0.90 | NOD1 (0.88) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL12980909 | 0.89 | NOD1 (0.65) | NOD1SLC6A5KMT2APLA2G2C | |
| SCHEMBL13641019 | 0.89 | NOD1 (0.65) | NOD1SLC6A5KMT2APLA2G2C | |
| SCHEMBL19049825 | 0.89 | NOD1 (0.85) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL19049824 | 0.89 | NOD1 (0.85) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL13974161 | 0.89 | NOD1 (0.65) | NOD1SLC6A5KMT2APLA2G2C | |
| SCHEMBL19049829 | 0.89 | NOD1 (0.85) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188479-A1 | APPARATUS AND METHODS FOR ADMINISTRATION OF A NAUSEOGENIC COMPOUND FROM A DRUG DELIVERY DEVICE | INTARCIA IRELAND LIMITED | 2020-06-18 | — | — | US | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188479-A1 | APPARATUS AND METHODS FOR ADMINISTRATION OF A NAUSEOGENIC COMPOUND FROM A DRUG DELIVERY DEVICE | CRH, OPRL1, LPXN | NOD1 2653/4885SLC6A5 527/4885FAAH 37/4885 |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | NOD1 2160/4885SLC6A5 2573/4885FAAH 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.